Abstract 232P
Background
Both abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and PSA response in patients with metastatic castration-resistant prostate cancer (MCRPC) regardless of previous treatment with chemotherapy (COU-AA301, COU-AA302, AFFIRM and PREVAIL). The data regarding the impact of these treatments in regional health services is scarce. This study assessed the survival outcomes in MCRPC patients in a regional health service in Victoria with the use of abiraterone and enzalutamide.
Methods
This retrospective clinical audit included 75 patients with the diagnosis of MCRPC treated with either abiraterone or enzalutamide between the period of January 1 2014 to December 31 2019 at Goulburn Valley Health. Patients were divided into two groups based on whether they received abiraterone or enzalutamide, and stratified according to ECOG performance, Gleason score, burden of disease, presence of visceral metastases and use of previous chemotherapy. The primary end point was PSA response. The secondary outcomes were PSA PFS, radiographic PFS, and OS.
Results
37 patients received enzalutamide, and the other 38 received abiraterone. Only 20% of patients in either group had visceral metastases. 32% of patients receiving enzalutamide had a high burden of disease, compared to 53% receiving abiraterone. 38% of patients in the enzalutamide group and 53% in the abiraterone group had received prior chemotherapy. PSA response rates were higher in the enzalutamide group than abiraterone group (70.3% vs 37.8%). Both PSA and radiographic PFS were longer in the enzalutamide group than abiraterone group; 7 months vs 5 months for both end points. OS was also found to be longer in patients receiving Enzalutamide; 30 months compared to 13 months in patients receiving Abiraterone.
Conclusions
Both abiraterone and enzalutamide have shown to result in significant PSA response rates, as well as PFS and OS benefit in MCRPC patients in the real-world setting, as reflected in previous clinical trials. The difference in responses and survival benefit between the groups are probably impacted by the unbalanced burden of disease and proportion of prior chemotherapy use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session